Wuhan Hvsen Biotechnology Co.,Ltd. (SHE:300871)
China
· Delayed Price · Currency is CNY 26.65
-0.53 (-1.95%)
Apr 29, 2026, 3:04 PM CST
Wuhan Hvsen Biotechnology Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Net Income | 286.33 | 253.16 | -20.16 | 16.78 | 52.71 | 132.87 | Upgrade
|
| Depreciation & Amortization | 120.3 | 120.3 | 113.29 | 120.39 | 62.57 | 28.54 | Upgrade
|
| Other Amortization | 1.01 | 1.01 | 0.76 | 0.63 | 0.12 | - | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | - | - | -0.01 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.61 | 0.61 | 0.21 | 0.67 | 0.51 | 0.06 | Upgrade
|
| Loss (Gain) From Sale of Investments | -10.09 | -10.09 | 15.45 | -25.37 | -7.01 | -4.4 | Upgrade
|
| Provision & Write-off of Bad Debts | 4.94 | 4.94 | -1.68 | 24.94 | 10.77 | -7.07 | Upgrade
|
| Other Operating Activities | -18.2 | 20.32 | 45.54 | 31.08 | 9.05 | 6.31 | Upgrade
|
| Change in Accounts Receivable | -43.45 | -43.45 | -210.12 | -109.82 | 14.44 | 21.69 | Upgrade
|
| Change in Inventory | -22.94 | -22.94 | -20.83 | -28.06 | 30.42 | -105.92 | Upgrade
|
| Change in Accounts Payable | -83.73 | -83.73 | 136.38 | 71.98 | -71.04 | 67.53 | Upgrade
|
| Change in Other Net Operating Assets | 2.61 | 2.61 | 4.26 | - | -0.94 | 18.31 | Upgrade
|
| Operating Cash Flow | 233.11 | 238.45 | 43.53 | 92.92 | 96.68 | 155.72 | Upgrade
|
| Operating Cash Flow Growth | 57.75% | 447.76% | -53.15% | -3.89% | -37.91% | 222.07% | Upgrade
|
| Capital Expenditures | -129.59 | -96.92 | -194.43 | -184.31 | -428.87 | -600.12 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.02 | 0.4 | 0.42 | - | 0.07 | 0.1 | Upgrade
|
| Investment in Securities | 65.36 | 34.58 | 84 | 69.85 | -330 | 410 | Upgrade
|
| Other Investing Activities | 7.83 | 7.1 | 8.19 | 14.16 | 9.25 | 4.87 | Upgrade
|
| Investing Cash Flow | -56.45 | -54.84 | -101.81 | -100.3 | -749.54 | -185.15 | Upgrade
|
| Short-Term Debt Issued | - | 38.45 | 56.59 | 53.92 | 221.37 | - | Upgrade
|
| Long-Term Debt Issued | - | 220 | 480 | 210.85 | - | 135.21 | Upgrade
|
| Total Debt Issued | 338.4 | 258.45 | 536.59 | 264.77 | 221.37 | 135.21 | Upgrade
|
| Long-Term Debt Repaid | - | -368.08 | -479.56 | -244.3 | -139.8 | -73.52 | Upgrade
|
| Total Debt Repaid | -377.08 | -368.08 | -479.56 | -244.3 | -139.8 | -73.52 | Upgrade
|
| Net Debt Issued (Repaid) | -38.68 | -109.63 | 57.04 | 20.47 | 81.57 | 61.69 | Upgrade
|
| Issuance of Common Stock | - | - | 16.35 | - | - | 700.96 | Upgrade
|
| Repurchase of Common Stock | -0.64 | -0.64 | -3.26 | -3.31 | -53.68 | - | Upgrade
|
| Common Dividends Paid | -48.89 | -49.92 | -59.16 | -58.63 | -62.48 | -47.94 | Upgrade
|
| Other Financing Activities | 8.72 | -0.05 | 3 | - | -0.01 | -4.63 | Upgrade
|
| Financing Cash Flow | -79.49 | -160.24 | 13.98 | -41.48 | -34.6 | 710.09 | Upgrade
|
| Foreign Exchange Rate Adjustments | -3.12 | -1.84 | -0.61 | -0.23 | -0.07 | -0.03 | Upgrade
|
| Net Cash Flow | 94.04 | 21.53 | -44.92 | -49.09 | -687.53 | 680.63 | Upgrade
|
| Free Cash Flow | 103.52 | 141.53 | -150.89 | -91.39 | -332.18 | -444.4 | Upgrade
|
| Free Cash Flow Margin | 5.95% | 8.42% | -12.57% | -8.96% | -32.48% | -44.61% | Upgrade
|
| Free Cash Flow Per Share | 0.51 | 0.72 | -0.91 | -0.55 | -2.01 | -2.68 | Upgrade
|
| Cash Income Tax Paid | 88.85 | 73.77 | 40.27 | 41.25 | 0.09 | 1.6 | Upgrade
|
| Levered Free Cash Flow | 103.96 | 87.6 | -159.99 | -223.53 | -217.62 | -467.49 | Upgrade
|
| Unlevered Free Cash Flow | 112.47 | 96.11 | -133.32 | -205.9 | -206.14 | -465.69 | Upgrade
|
| Change in Working Capital | -151.8 | -151.8 | -109.88 | -76.2 | -32.04 | -0.58 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.